IOL Chemicals and Pharmaceuticals Limited (NSE:IOLCP)
India · Delayed Price · Currency is INR 118.21
-2.96 (-2.44%)
May 22, 2026, 3:30 PM IST
NSE:IOLCP Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 23,191 | 20,792 | 21,328 | 22,171 | 21,840 |
Other Revenue | 213.8 | - | - | - | - |
| 23,404 | 20,792 | 21,328 | 22,171 | 21,840 | |
Revenue Growth (YoY) | 12.56% | -2.51% | -3.80% | 1.52% | 11.03% |
Cost of Revenue | 14,871 | 14,013 | 14,041 | 15,605 | 15,812 |
Gross Profit | 8,533 | 6,779 | 7,287 | 6,566 | 6,028 |
Selling, General & Admin | 2,483 | 2,183 | 2,027 | 1,686 | 1,415 |
Other Operating Expenses | 3,147 | 2,573 | 2,954 | 2,617 | 2,019 |
Operating Expenses | 6,432 | 5,477 | 5,610 | 4,765 | 3,867 |
Operating Income | 2,101 | 1,303 | 1,677 | 1,801 | 2,161 |
Interest Expense | -145.5 | -99 | -108.4 | -106.9 | -24.3 |
Interest & Investment Income | - | 110.4 | 143.2 | 167.3 | 182 |
Currency Exchange Gain (Loss) | - | 83.4 | 130.8 | 70.6 | 104.4 |
Other Non Operating Income (Expenses) | - | -18.5 | -28.6 | -42.2 | -25.1 |
EBT Excluding Unusual Items | 1,956 | 1,379 | 1,814 | 1,890 | 2,398 |
Gain (Loss) on Sale of Investments | - | 0.2 | 0.2 | 2.3 | 0.2 |
Gain (Loss) on Sale of Assets | - | 1 | 1.4 | -3.3 | -2.4 |
Asset Writedown | - | -0.8 | -0.4 | -2.6 | -8.5 |
Other Unusual Items | -112.1 | - | 1.1 | 0.3 | -139 |
Pretax Income | 1,844 | 1,380 | 1,817 | 1,887 | 2,249 |
Income Tax Expense | 467.2 | 368.9 | 472.2 | 495.1 | 571.8 |
Net Income | 1,376 | 1,011 | 1,344 | 1,391 | 1,677 |
Net Income to Common | 1,376 | 1,011 | 1,344 | 1,391 | 1,677 |
Net Income Growth | 36.18% | -24.82% | -3.38% | -17.02% | -62.28% |
Shares Outstanding (Basic) | 293 | 294 | 294 | 294 | 294 |
Shares Outstanding (Diluted) | 293 | 294 | 294 | 294 | 294 |
Shares Change (YoY) | -0.02% | - | - | - | 0.64% |
EPS (Basic) | 4.69 | 3.44 | 4.58 | 4.74 | 5.71 |
EPS (Diluted) | 4.69 | 3.44 | 4.58 | 4.74 | 5.71 |
EPS Growth | 36.34% | -24.89% | -3.38% | -17.02% | -62.52% |
Free Cash Flow | 413.3 | -349.3 | 156.1 | -895.5 | -602.4 |
Free Cash Flow Per Share | 1.41 | -1.19 | 0.53 | -3.05 | -2.05 |
Dividend Per Share | - | 0.800 | 1.000 | 0.800 | 0.800 |
Dividend Growth | - | -20.00% | 25.00% | - | -33.33% |
Gross Margin | 36.46% | 32.61% | 34.17% | 29.61% | 27.60% |
Operating Margin | 8.98% | 6.27% | 7.86% | 8.12% | 9.90% |
Profit Margin | 5.88% | 4.86% | 6.30% | 6.28% | 7.68% |
Free Cash Flow Margin | 1.77% | -1.68% | 0.73% | -4.04% | -2.76% |
EBITDA | 2,904 | 2,008 | 2,295 | 2,253 | 2,584 |
EBITDA Margin | 12.41% | 9.66% | 10.76% | 10.16% | 11.83% |
D&A For EBITDA | 802.3 | 705.1 | 617.8 | 452.2 | 422.8 |
EBIT | 2,101 | 1,303 | 1,677 | 1,801 | 2,161 |
EBIT Margin | 8.98% | 6.27% | 7.86% | 8.12% | 9.90% |
Effective Tax Rate | 25.34% | 26.74% | 26.00% | 26.24% | 25.43% |
Revenue as Reported | 23,404 | 21,016 | 21,629 | 22,427 | 22,161 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.